Literature DB >> 26216320

Outbreak of Mycoplasma pneumoniae-Associated Stevens-Johnson Syndrome.

Daniel Olson1, Louise K Francois Watkins2, Alicia Demirjian2, Xia Lin2, Christine C Robinson3, Kristin Pretty3, Alvaro J Benitez4, Jonas M Winchell4, Maureen H Diaz4, Lisa A Miller5, Teresa A Foo6, Melanie D Mason7, Ursula L Lauper8, Oren Kupfer9, Jeffrey Kennedy10, Mary P Glodé9, Preeta K Kutty4, Samuel R Dominguez9.   

Abstract

BACKGROUND: Stevens-Johnson syndrome (SJS) is an uncommon, sporadic disease and outbreaks are rare. In November 2013, an outbreak of SJS was identified at Children's Hospital Colorado.
METHODS: Outbreak cases were children aged 5-21 with a discharge diagnosis of SJS admitted from September 1 to November 30, 2013. Medical charts were reviewed using standardized data collection forms. Respiratory specimens were tested for viruses and Mycoplasma pneumoniae (Mp) by polymerase chain reaction (PCR). We conducted a separate 4-year retrospective case-control study comparing hospitalized SJS cases with and without evidence of Mp infection.
RESULTS: During the outbreak, 8 children met SJS criteria. Median age was 11.5 years (range 8-16 years); 5 (63%) were boys and 5 (63%) were Mp-PCR-positive. Of the 5 PCR-positive children, none had preceding medication exposure, and all had radiographic pneumonia. All outbreak Mp isolates were macrolide susceptible. The retrospective case-control analysis showed that Mp-associated SJS episodes (n = 17) were more likely to have pneumonia (odds ratio [OR] 7.5, confidence interval [CI] 1.6–35.1), preceding respiratory symptoms (OR 30.0, CI 3.3–269.4) [corrected] an erythrocyte sedimentation rate ≥35 mg/dL (OR 22.8, CI 2.1-244.9), and ≤3 affected skin sites (OR 4.5, CI 1.2-17.4) than non-Mp-associated SJS episodes (n = 23).
CONCLUSIONS: We report the largest outbreak of SJS in children, which was also predominately associated with Mp infection. Mp-associated SJS was associated with a distinct clinical presentation that included less extensive skin disease, an elevated erythrocyte sedimentation rate, and evidence of a preceding respiratory infection.
Copyright © 2015 by the American Academy of Pediatrics.

Entities:  

Mesh:

Year:  2015        PMID: 26216320      PMCID: PMC4516944          DOI: 10.1542/peds.2015-0278

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  55 in total

1.  Fuchs syndrome associated with Mycoplasma pneumoniae (Stevens-Johnson syndrome without skin lesions).

Authors:  Patrick Michael Meyer Sauteur; Ursula Gansser-Kälin; Stephan Lautenschlager; Philippe Goetschel
Journal:  Pediatr Dermatol       Date:  2010-07-29       Impact factor: 1.588

2.  Erythema exudativum sultiforme (Hebra) bullous type.

Authors:  M W C FLETCHER; R C HARRIS
Journal:  J Pediatr       Date:  1945-11       Impact factor: 4.406

3.  Pneumonia and erythema multiforme exudativum; report of four cases and three autopsies.

Authors:  M FINLAND; L S JOLLIFFE; F PARKER
Journal:  Am J Med       Date:  1948-04       Impact factor: 4.965

4.  Comparison of laboratory diagnostic procedures for detection of Mycoplasma pneumoniae in community outbreaks.

Authors:  Kathleen A Thurman; Nicholas D Walter; Stephanie B Schwartz; Stephanie L Mitchell; Michael T Dillon; Andrew L Baughman; Meredith Deutscher; John P Fulton; Jon E Tongren; Lauri A Hicks; Jonas M Winchell
Journal:  Clin Infect Dis       Date:  2009-05-01       Impact factor: 9.079

5.  Erythema multiforme exudativum; the Stevens-Johnson syndrome.

Authors:  E DRESNER
Journal:  Lancet       Date:  1949-12-03       Impact factor: 79.321

Review 6.  Oral manifestations of erythema multiforme.

Authors:  Lilibeth Ayangco; Roy S Rogers
Journal:  Dermatol Clin       Date:  2003-01       Impact factor: 3.478

7.  Epidemiology of Mycoplasma pneumoniae infection in families.

Authors:  H M Foy; J T Grayston; G E Kenny; E R Alexander; R McMahan
Journal:  JAMA       Date:  1966-09-12       Impact factor: 56.272

8.  Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years' experience.

Authors:  Rachel Forman; Gideon Koren; Neil H Shear
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

9.  Stevens-Johnson syndrome in Thai children: a 29-year study.

Authors:  Srisupalak Singalavanija; Wanida Limpongsanurak
Journal:  J Med Assoc Thai       Date:  2011-08

Review 10.  Mycoplasma pneumoniae infections and Stevens-Johnson syndrome. Report of eight cases and review of the literature.

Authors:  M Levy; N H Shear
Journal:  Clin Pediatr (Phila)       Date:  1991-01       Impact factor: 1.168

View more
  24 in total

1.  A Retrospective Cohort Study of the Management and Outcomes of Children Hospitalized with Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis.

Authors:  James W Antoon; Jennifer L Goldman; Samir S Shah; Brian Lee
Journal:  J Allergy Clin Immunol Pract       Date:  2018-05-30

2.  Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis reported after vaccination, 1999-2017.

Authors:  John R Su; Penina Haber; Carmen S Ng; Paige L Marquez; Graça M Dores; Silvia Perez-Vilar; Maria V Cano
Journal:  Vaccine       Date:  2019-12-20       Impact factor: 3.641

Review 3.  Mycoplasma pneumoniae from the Respiratory Tract and Beyond.

Authors:  Ken B Waites; Li Xiao; Yang Liu; Mitchell F Balish; T Prescott Atkinson
Journal:  Clin Microbiol Rev       Date:  2017-07       Impact factor: 26.132

4.  Epidemiology and Molecular Characteristics of Mycoplasma pneumoniae During an Outbreak of M. pneumoniae-associated Stevens-Johnson Syndrome.

Authors:  Louise K Francois Watkins; Daniel Olson; Maureen H Diaz; Xia Lin; Alicia Demirjian; Alvaro J Benitez; Jonas M Winchell; Christine C Robinson; Kirk A Bol; Mary P Glodé; Samuel R Dominguez; Lisa A Miller; Preeta K Kutty
Journal:  Pediatr Infect Dis J       Date:  2017-06       Impact factor: 2.129

5.  Mycoplasma pneumoniae Among Children Hospitalized With Community-acquired Pneumonia.

Authors:  Preeta K Kutty; Seema Jain; Thomas H Taylor; Anna M Bramley; Maureen H Diaz; Krow Ampofo; Sandra R Arnold; Derek J Williams; Kathryn M Edwards; Jonathan A McCullers; Andrew T Pavia; Jonas M Winchell; Stephanie J Schrag; Lauri A Hicks
Journal:  Clin Infect Dis       Date:  2019-01-01       Impact factor: 9.079

Review 6.  Molecular Tools for Typing Mycoplasma pneumoniae and Mycoplasma genitalium.

Authors:  Roger Dumke
Journal:  Front Microbiol       Date:  2022-06-02       Impact factor: 6.064

Review 7.  SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation.

Authors:  Katie D White; Riichiro Abe; Michael Ardern-Jones; Thomas Beachkofsky; Charles Bouchard; Bruce Carleton; James Chodosh; Ricardo Cibotti; Robert Davis; Joshua C Denny; Roni P Dodiuk-Gad; Elizabeth N Ergen; Jennifer L Goldman; James H Holmes; Shuen-Iu Hung; Mario E Lacouture; Rannakoe J Lehloenya; Simon Mallal; Teri A Manolio; Robert G Micheletti; Caroline M Mitchell; Maja Mockenhaupt; David A Ostrov; Rebecca Pavlos; Munir Pirmohamed; Elena Pope; Alec Redwood; Misha Rosenbach; Michael D Rosenblum; Jean-Claude Roujeau; Arturo P Saavedra; Hajirah N Saeed; Jeffery P Struewing; Hirohiko Sueki; Chonlaphat Sukasem; Cynthia Sung; Jason A Trubiano; Jessica Weintraub; Lisa M Wheatley; Kristina B Williams; Brandon Worley; Wen-Hung Chung; Neil H Shear; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2018 Jan - Feb

8.  Mycoplasma pneumoniae Genotypes and Clinical Outcome in Children.

Authors:  Christoph Berger; Roger Dumke; Patrick M Meyer Sauteur; Elena Pánisová; Michelle Seiler; Martin Theiler
Journal:  J Clin Microbiol       Date:  2021-06-18       Impact factor: 5.948

Review 9.  Mechanisms of Severe Cutaneous Adverse Reactions: Recent Advances.

Authors:  Teresa Bellón
Journal:  Drug Saf       Date:  2019-08       Impact factor: 5.228

Review 10.  Severe Delayed Drug Reactions: Role of Genetics and Viral Infections.

Authors:  Rebecca Pavlos; Katie D White; Celestine Wanjalla; Simon A Mallal; Elizabeth J Phillips
Journal:  Immunol Allergy Clin North Am       Date:  2017-11       Impact factor: 3.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.